Cost-utility Analysis of a Consensus and Evidence-based Medication Review to Optimize and Potentially Reduce Psychotropic Drug Prescription in Institutionalized Dementia Patients


 BACKGROUND: Growing evidence shows the effects of psychotropic drugs on the evolution of dementia. Until now, only a few studies have evaluated the cost‑effectiveness of psychotropic drugs in institutionalized dementia patients. This study aims to assess the cost‑utility of intervention based on consensus between specialized caregivers involved in the management of dementia patients for optimizing and potentially reducing the prescription of inappropriate psychotropic drugs in this population. This analysis was conducted using the Monitoring and Assessment Framework for the European Innovation Partnership on Active and Healthy Ageing (MAFEIP) tool.METHODS: The MAFEIP tool builds up from a variety of surrogate endpoints commonly used across different studies in order to estimate health and economic outcomes in terms of incremental changes in quality adjusted life years (QALYs), as well as health and social care utilization. Cost estimates are based on scientific literature and expert opinion; they are direct costs and include medical visits, hospital care, medical tests and exams and drugs administered, among other concepts. The healthcare costs of patients using the intervention were calculated by means of a medication review that compared patients' drug‑related costs before, during and after the use of the intervention. The cost‑utility analysis was performed from the perspective of a health care system with a time horizon of 12 months.RESULTS: The tool calculated the incremental cost‑effectiveness ratio (ICER) of the intervention, revealing it to be dominant, or rather, better (more effective) and cheaper than the current (standard) care. The ICER of the intervention was in the lower right quadrant, making it an intervention that is always accepted even with the lowest given Willingness to Pay (WTP) threshold value (€15,000). CONCLUSIONS: The results of this study show that the intervention was dominant, or rather, better (more effective) and cheaper than the current (standard) care. This dominant intervention is therefore recommended to interested investors for systematic application.

Psychotropic drugs are not the only cause for concern in institutionalized dementia patients; polypharmacy itself is another important factor that must be taken into account to prevent adverse events and potentially inappropriate prescriptions in this population (7).
Numerous studies have demonstrated the effectiveness of medication reviews conducted either by a pharmacist alone or a multidisciplinary team in reducing inappropriate medication (8)(9)(10) and its impact (11) (12), either in terms of cost reduction (13) and increased quality of life (14) (12), although not always with favorable results (15) (16) (17).
While several studies have demonstrated the effectiveness of interventions aimed at reducing the use of psychotropic drugs in institutionalized dementia patients (18) (19) (20) (21), few have evaluated their costeffectiveness or the impact of these interventions on patients' quality of life (22). Additionally, despite showing a reduction in the consumption of psychotropic drugs, no clear bene t has been proven (or the results are contradictory). One potential explanation for this is that these studies evaluated different types of interventions and, therefore, the results will necessarily differ. Another possibility is that they evaluated the cost-utility of a combination of interventions that, in addition to a medication review, included behavioral support intervention.
.For example, in a study by Ballard et al (23), patientcentered intervention resulted in increased quality of life even though there was no signi cant reduction in the consumption of psychotropic drugs in either the intervention or control group. These outcomes are aligned with a 2017 study by Ballard et al (24) in which social interaction intervention was reported as the only type of intervention that led to increased quality of life. The costanalysis of the intervention revealed a signi cant reduction in social and healthcare costs in the intervention group as compared with the control group.
Richter et al (25), on the other hand, did not analyze costeffectiveness in their study because the results of the control group were better than those of the intervention group. Harrison et al found that greater exposure to psychotropic drugs is linked to lower quality of life (26) in contrast with the ndings of Ballard et al (24), in which the reduced use of psychotropic drugs in dementia patients worsened quality of life. However, in another study, Ballard et al (27) concluded that the discontinuation of antipsychotics may have little or no effect on overall cognitive function. Discontinuation may make no difference to adverse events or quality of life. In a 2016 study, Ballard et al (28) used mortality analysis to review psychotropic drugs linked to social intervention and identi ed a reduction in mortality as compared to receiving no intervention.
This study aims to assess the cost-effectiveness of an intervention based on consensus between the primary care pharmacists, GPs and nursing home physicians and nurses involved in the management of dementia patients for optimizing and potentially reducing the prescription of inappropriate psychotropic drugs in this population. The analysis was conducted using the Monitoring and Assessment Framework for the European Innovation Partnership on Active and Healthy Ageing (MAFEIP) tool (29) (30).

Intervention analyzed
The details of the actual intervention analyzed in this study are described elsewhere (31). In short, the patients included were institutionalized dementia patients with pharmacological treatment with one or more psychotropic drugs from the Anatomical Therapeutic Chemical Classi cation System (ATC) code N of the World Health Organization (WHO) (32) for three months or longer. It was a structured, patientcentered medication review by a multidisciplinary team (primary care pharmacists, GPs, nursing home physicians and nurses) aimed at reducing inappropriate psychotropic drug prescriptions based on a therapeutic guideline for treating BPSD (created by a multidisciplinary team) as compared to standard care. Before implementing the medication review, one general practitioner (GP) and one primary care pharmacist underwent a training phase focused on managing patients with BPSD. Then, before each scheduled visit with the nursing home physician and nurse, the medication the patient was receiving was evaluated by the GP and pharmacist to detect any incidents related to the prescription (e.g., duplicates, inappropriate drugs) and to determine which prescriptionrelated aspects required evaluation of the patient for decisionmaking (continue or discontinue a drug). As for the working session in the nursing home, before conducting the medication review (of all drugs included in the therapeutic plan), the GP and pharmacist met with the nursing home physician and nurse to establish the patient's current status with regard to his/her prognosis, level of dependence, and frailty. This was done to facilitate decisions on the need to adapt the intensity of treatment, change treatment, or discontinue treatment based on the riskbene t ratio for the patient. Patient assessment included the severity of dementia (Global Dementia Scale [GDS]), level of dependence (Barthel index score), cognitive state (Pfeiffer test), and prognosis (in endo ife patients). Treatment assessment included the indication, effectiveness, and safety (duplicates, interactions, contraindications) of the drugs prescribed. Based on these evaluations, changes in the patient's treatment plan considered to be appropriate and relevant were proposed. Followup of the consensus changes was carried out at one and six months to determine whether any psychotropic drugs that had been discontinued after the interview should be restarted, the dosage of drugs that had been reduced should be increased, or a new psychotropic drug should be initiated. Over the course of the intervention, the mean number of drugs prescribed per patient decreased from 8.04 at baseline to 5.86 at 6 months and from 2.71 to 2.01 for psychotropic drugs.

Model input
The analysis was conducted using the Monitoring and Assessment Framework for the European Innovation Partnership on Active and Healthy Ageing (MAFEIP) tool. In MAFEIP Users Guide Manual (33) describes the basic principles of the tool to better understand the tool and how it works. In this manual is described the MAFEIP tool is founded on the principles of Decision Analytic Modelling (DAM), an approach commonly used to evaluate the health and economic impact of healthcare innovations. More precisely, MAFEIP is based, by default, on a generic threestate Markov model, which provides the exibility required to be adaptable to a large number of studies that focus on a variety of objectives, implement different interventions and target different cohorts of individuals with different demographic or disease characteristics.
The outcomes for the intervention and control group are calculated by simulating the health status of the target population as it transitions through the three health states de ned in the Markov model: baseline health, deteriorated health, and dead ( Fig. 1). Each health state is de ned by an amount of resource use and quality of life (utility). This represents the average resource use and quality of life of a patient in that health state.
In the simulation, the population moves through the Markov states based on four transition probabilities: 1) Transition from the baseline health state to the deteriorated health state represents a patient becoming ill (i.e., the incidence of the deteriorated health condition); 2) Patients move from the deteriorated health state to the baseline health state when their illness is cured (i.e., the rate of recovery back to baseline health); 3) Transition to the dead state from the baseline state (i.e., baseline mortality in the target population); 4) Transition to the dead state from the deteriorated health state (i.e., excess mortality in the population with deteriorated health).
The MAFEIP tool builds up from a variety of surrogate endpoints commonly used across different studies in order to estimate health and economic outcomes in terms of incremental changes in quality adjusted life years (QALYs), as well as health and social care utilization.
A highly adaptable Markov model with initially three mutually exclusive health states (baseline health, deteriorated health and death) forms the basis of the tool, which draws from an extensive database of epidemiological, economic and effectiveness data. It also allows for further customization through remote data entry, thus enabling more accurate and contextspeci c estimation of intervention impact.
The impact of parameter uncertainty on intervention outcomes can be assessed through probabilistic sensitivity analysis and deterministic scenario analysis.
In our study, the threestate Markov model of the MAFEIP tool was used to describe patients without dementia (baseline health state), patients with dementia (deteriorated health state), and death. The study combined data from nursing homes with data collected from external sources to populate the model with values for transition probabilities and relative risk of mortality. Incidence rates were derived from data on the prevalence of dementia in institutionalized patients in our reference area. Moreover, estimates on mortality rates were derived from the ndings of the DARTAD (2) clinical trial, which reported higher survival rates in patients who were given placebo drugs instead of neuroleptics.

Costs and utility values
Cost estimates were based on scienti c literature, the eSalud database (34) and expert opinion. The cost estimates are direct costs, including medical visits, hospital care, medical tests and exams and drugs administered, among other concepts.
The healthcare costs of patients using the intervention were calculated by means of a medication review that compared drugrelated costs of the patients before, during, and after the use of the intervention.
Intervention cost estimates were based on the amount of time spent by the physician, pharmacist, and/or nurse with the patients.
Regarding utility values, the study did not focus on utility calculations but used secondary sources to provide general and averaged estimates (35). Utility values of the baseline group describe data collected on healthrelated quality of life (HRQoL) (36) for people from the same country and of the same age group who do not have dementia. Since the intervention has been shown to have an impact on mortality rates rather than HRQoL, utility values for the control group and intervention group are similar. (Utility for control and intervention group: baseline 0.70 and deteriorated 0.27).

Model output
The costutility analysis was performed from the perspective of a health care system with a time horizon of 12 months. It was focused on calculating the incremental costeffectiveness ratio (ICER) of the intervention and comparing it to the standard of care. As for secondary outcomes, the analysis also calculates the Willingness to Pay (WTP).

Model and base case
As previously mentioned, the use case takes into account the threestate Markov model depicted in Fig. 1.
Each health state describes institutionalized patients between 65 and 90 years of age. The baseline health state describes patients without dementia whereas the deteriorated health state describes patients with dementia. Records show that the prevalence of dementia in institutionalized patients in our reference area is 40%. This is adopted as the incidence rate for both the control and intervention group since the intervention does not focus on reducing the rate of incidence of dementia and therefore does not affect it. In this use case, it was assumed that patients cannot completely recover once they already have dementia and, thus, recovery rates were set to 0 for both groups. (Transition probabilities: intervention and control group, incidence rate: 40 and recovery rate: 0).
Mortality rate estimates were derived from the ndings of the DARTAD (2) clinical trial, which reported higher survival rates in patients who were given placebo drugs instead of neuroleptics. Based on the clinical trial, the cumulative probability of survival at 12 months was 70% in the control group (those who continued treatment with neuroleptics) vs. 77% in the intervention group (those who were given placebos). Moreover, the results show that the difference between the groups was greater after longer periods: at 24 months, survival rate was 46% vs. 71% and at 36 months, it was 30% vs. 59%. The mortality rates were obtained by rst calculating the mean of all the survival rates given (49% vs. 69% or 0.49 vs. 0.69) and then subtracting the mean survival rates from 1. (Calculated mortality rate: 0.51 vs. 0.31).

Page 7/16
The MAFEIP tool uses another measure for estimating mortality in a given population: the relative risk of mortality (RR). This is calculated by dividing the mortality rates in the use case by the mortality for a reference condition. In this particular use case, the reference condition is the agedependent, allcause mortality of the Spanish population as recorded in the Human Mortality Database. The RR values were a baseline health of 1 and deteriorated health of 1.31 for the intervention group, and 1 and 1.51 for the control group, respectively.
Patients in the baseline health state had an RR of 1. This is the default value and it prompts the tool to simply use data that is stored in the Human Mortality Database. Those in the deteriorated health state, however, were given an RR greater than 1. Choosing the value RR > 1 leads the tool to interpret this as excess mortality to be added to the existing data from the Human Mortality Database (i.e., mortality rate from database + excess mortality from use of neuroleptics).
Across all patient groups, those who had dementia (deteriorated state) and were given neuroleptics (control group) had the highest mortality rate (1.51 is higher than baseline and higher than the intervention group). Mean patient age was 87.09 years (SD: 6.795), and 75% (n = 180) were women. There were no signi cant differences in patient age between the participating nursing homes.

Computing the costs
Intervention cost estimates were based on the amount of time spent by the physician, pharmacist, and/or nurse with the patients. The total sum of intervention costs calculated from the staff spending 30 minutes with each patient, in accordance with the therapeutic plan, came to €11,654.40 or €48.56 per patient. Since the patient does not have to pay for the therapeutic guide itself before it is used, the intervention oneoff costs were left at 0.   As shown in the Table 2, baseline health costs were left at 0 since the intervention only focuses on patients that are already in a deteriorated health state (they already have dementia). Since the use case focused on comparing costs related to drug use for institutionalized dementia patients, additional societal costs such as transport were not taken into account (e.g. if they live far away and have to drive to another city to be admitted to a hospital or the costs of relatives acting as caretakers at home). Thus, in this example, societal costs are the same as the healthcare costs.
The costs of the intervention group were calculated as the mean of the costs recorded after intervention.

Results
The incremental costs by age all fall below zero (negative), as shown in Fig. 2. Negative incremental cost can be interpreted as "savings" that the intervention may generate, whereas positive results can be interpreted as additional costs required by the intervention as compared to standard care. The gure below shows that the incremental costs by age are all negative, which implies that the intervention (having a therapeutic guideline and plan) is cheaper than standard care (continuing with neuroleptic prescriptions only). The graph below also shows that the costs remain negative across the age range (65 to 90 years), although they do increase as age increases (depicted by upward curve).
The graph portraying incremental effects by age (Fig. 3) shows how many QALYs each age group in the target group was able to bene t from if the intervention was used. Since this use case did not focus on impact on QALYs, the values in the graph remain close to the earlier input value (0.7 baseline and 0.27 deteriorated state). The graph also illustrates that QALYs are lower at an older age. The ICER takes into account both the potential incremental costs and incremental effects that intervention may provide. In this example, the ICER is described as "dominant" and its exact value (represented by the blue dot in Fig. 6) is located in the lowerright quadrant of the graph. If an intervention is "dominant" it means that it is better (more effective) and cheaper than the current (standard) care. It also means that the intervention is (always) accepted and, therefore, possibly of value to interested investors.
Moreover, the WTP threshold describes the maximum amount patients are willing to pay given a certain QALY. When the ICER is less than the WTP, it means that the intervention is cheaper than what patients are willing to pay for it (also making the intervention accepted). The graphs illustrate how likely it is that a patient from a given age group and health state will remain in an alive state or move to the dead state. Mortality rates of patients without dementia (baseline health state) were set to the default value of 1. The tool then took age and countrydependent, all-cause mortality rates from the Human Mortality Database.
In order to better compare the effect of the intervention (therapeutic plan) vs. current care (neuroleptics) speci cally for patients in the deteriorated state (with dementia), the plots depicting the baseline health states were deselected (Fig. 8). The graph shows that there are better chances of remaining in an alive state when using the intervention rather than current care. Figure 9 describes the probability of patients moving to the dead state (by age group). The graph illustrates how patients using the intervention have lower chances of dying when compared to patients still being given neuroleptics (current care).

Discussion
This study aims to assess the cost-effectiveness of an intervention based on consensus between the primary care pharmacists, GPs and nursing home physicians and nurses involved in the management of dementia patients for optimizing and potentially reducing the prescription of inappropriate psychotropic drugs in this population. Intervention based on speci c, evidencebased therapeutic guidelines designed by a multidisciplinary team and implemented through consensus together with a patientcentered clinical medication review has proven to be a dominant or costeffective intervention. This means that the intervention is better (more effective) and cheaper than the current (standard) care. The results describe an intervention that is always recommended to be accepted, even with the lowest given WTP threshold value (€15,000).
The positive results obtained in this costutility analysis are due to the number of drugs and psychotropic drugs deprescribed and, based on the evidence (2), their impact on mortality outcomes in institutionalized dementia patients. The mean number of drugs prescribed per patient decreased from 8.04 at baseline to 5.86 at six months and from 2.71 to 2.01 for psychotropic drugs.
This reduction could be due to the methodology used: patientcentered clinical medication review by a multidisciplinary team, decisionmaking based on a single guide used by all team members, and the solving of different issues through an onsite meeting with all the managers responsible for patient care, in which the therapeutic objectives were shared, thus favoring joint decision making. A systematic review by Kwak et al (17) that analyzed all the economic studies on medication review interventions conducted by pharmacists in nursing homes did not obtain a clear conclusion due to the heterogeneity of the studies included. In the discussion, however, it was pointed out that studies with positive economic results were based on a collaborative model, in which all the team members had a de ned role, the objectives and guides were shared and an effective communication method was employed.
Speci cally, as regards the reduction of psychotropic drugs, it should be noted that at the beginning of the study we veri ed the prevalence of psychotropic prescriptions and polypharmacy in dementia patients and that it was higher than that described by other authors (38) (39) (40). For this reason, the intervention is probably costeffective at the time of implementation and after six months. The impact of the intervention and its costutility after a longer period and when the prevalence of drugs is lower still must be studied.
This fact might be re ected in the Ballard et al study (24) in which discontinuance of psychotropic drugs in the study population had a negative impact on patients' quality of life. In the discussion, the authors note that the results must be due to a general reduction in the prescription of psychotropic drugs over the previous ve years, leading to a low prevalence (18%) of psychotropic drugs among the study population.
This shows that patients that currently have a psychotropic drug prescribed probably have more severe neuropsychiatric symptoms than in the past.
The results obtained from this costutility study cannot be compared to the results of other costeffectiveness studies due to the different methodologies used and interventions performed (28) (23) (41) (42), as well as the type of patients included (23) and results analyzed.
One limitation of this analysis is the very nature of the study since it is not a clinical trial but a pre/post intervention study. Another limitation, common to all costutility analyses, is that societal bene ts and costs are not taken into account. As for its strengths, this study makes it possible to compare different health interventions and policies.

Conclusion
The results of this analysis showed that our intervention was dominant, that is, better (more effective) and cheaper than the current (standard) care. This also means that the intervention is always accepted and, therefore, possibly of value to interested investors since the prevalence of dementia is on the rise due to an everlarger aging population. Having demonstrated its costeffectiveness, the implementation of a guideline for reducing prescriptions based on the consensus of all the professionals involved in patients' care leads to proven bene ts for both the patients themselves and the healthcare system.